Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3'-untranslated region (3'-UTR) of the Prostaglandin-endoperoxide synthase 2 (PTGS2 or COX-2) messenger RNA is a critical regulatory hub for the post-transcriptional control of COX-2 expression (Dixon et al., 2001, J. Biol. Chem.). It contains multiple AU-rich elements (AREs) that serve as binding sites for various RNA-binding proteins (RBPs) such as HuR (ELAVL1), which stabilizes the transcript, and Tristetraprolin (TTP), which promotes its degradation (Young et al., 2013, Adv. Cancer Res.). In many cancers and chronic inflammatory conditions, the COX-2 mRNA is pathologically stabilized, leading to sustained high levels of the COX-2 enzyme and subsequent overproduction of pro-inflammatory prostaglandins (Sheng et al., 2001, J. Biol. Chem.). Targeting this region or its associated binding proteins offers a therapeutic strategy to reduce COX-2 expression at the source, rather than just inhibiting the enzyme's activity (Meisner et al., 2007, ChemBioChem). Experimental approaches include the use of small molecules like MS-444 that disrupt RBP-ARE interactions, antisense oligonucleotides, and microRNA mimics (Blanco et al., 2016, Oncotarget). This target is particularly relevant in oncology, where COX-2 overexpression drives tumor progression, angiogenesis, and immune evasion (Wang & Dubois, 2010, Gut). By modulating the stability and translation of the mRNA, researchers aim to achieve more selective and potent anti-inflammatory and anti-tumor effects.
Modulation of mRNA stability and translation efficiency through interaction with RNA-binding proteins (RBPs) and microRNAs (miRNAs) at AU-rich elements (AREs).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin-endoperoxide synthase 2 mRNA 3'-untranslated region (PTGS2 mRNA 3'-UTR).